Xtant Medical Holdings, Inc.
XTNT Healthcare Medical Devices
Xtant Medical Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $133.9 million, up 14.2% from fiscal 2024. In the quarter to June 2026, revenue fell 35.0%, EPS fell 333.3%, free cash flow fell 882.0% and total debt fell 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow XTNT
Xtant Medical Holdings, Inc. (XTNT) EV/Sales
As of 16 October 2026, Xtant Medical Holdings, Inc. (XTNT) trades at a EV/Sales of 0.5×. Over the past ten years it has ranged from 0.5× (October 2026) to 7.0× (March 2016) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | 17.93% |
| FY2024 | 0.7× | (57.78%) |
| FY2023 | 1.8× | 74.91% |
| FY2022 | 1.0× | 23.16% |
| FY2021 | 0.8× | (13.11%) |
| FY2020 | 0.9× | (34.60%) |
| FY2019 | 1.4× | (33.65%) |
| FY2018 | 2.2× | (15.75%) |
| FY2017 | 2.6× | 70.78% |
| FY2016 | 1.5× | (31.36%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | 1.60% |
| Mar 2026 | 0.6× | (26.20%) |
| Dec 2025 | 0.9× | 6.67% |
| Sep 2025 | 0.8× | (19.81%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLIS Talis Biomedical Corporation compare | −55.3× |
| NNOX Nano-X Imaging Ltd. compare | 0.4× |
| XTNT Xtant Medical Holdings, Inc. | 0.5× |
| CVRX CVRx, Inc. compare | 0.5× |
| RPID Rapid Micro Biosystems, Inc. compare | 1.0× |
| TELA TELA Bio, Inc. compare | 1.1× |
| SNWV Sanuwave Health Inc. compare | 1.2× |
| SRTS Sensus Healthcare, Inc. compare | 2.1× |
| MDAI Spectral AI, Inc. compare | 3.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)